These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 26479437)

  • 1. Systemic lupus erythematosus: review of synthetic drugs.
    Tsang-A-Sjoe MW; Bultink IE
    Expert Opin Pharmacother; 2015; 16(18):2793-806. PubMed ID: 26479437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
    de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
    Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pragmatic approaches to therapy for systemic lupus erythematosus.
    Xiong W; Lahita RG
    Nat Rev Rheumatol; 2014 Feb; 10(2):97-107. PubMed ID: 24166241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
    Fanouriakis A; Kostopoulou M; Andersen J; Aringer M; Arnaud L; Bae SC; Boletis J; Bruce IN; Cervera R; Doria A; Dörner T; Furie RA; Gladman DD; Houssiau FA; Inês LS; Jayne D; Kouloumas M; Kovács L; Mok CC; Morand EF; Moroni G; Mosca M; Mucke J; Mukhtyar CB; Nagy G; Navarra S; Parodis I; Pego-Reigosa JM; Petri M; Pons-Estel BA; Schneider M; Smolen JS; Svenungsson E; Tanaka Y; Tektonidou MG; Teng YO; Tincani A; Vital EM; van Vollenhoven RF; Wincup C; Bertsias G; Boumpas DT
    Ann Rheum Dis; 2024 Jan; 83(1):15-29. PubMed ID: 37827694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
    Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
    Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus.
    Paredes-Ruiz D; Martin-Iglesias D; Ruiz-Irastorza G
    Expert Rev Clin Immunol; 2024 Apr; 20(4):359-373. PubMed ID: 38112074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
    Ugarte A; Danza A; Ruiz-Irastorza G
    Curr Opin Rheumatol; 2018 Sep; 30(5):482-489. PubMed ID: 29870497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [EULAR recommendations 2023 on the treatment of systemic lupus erythematosus -Implications for treatment in Germany].
    Mucke J; Aringer M
    Z Rheumatol; 2024 Aug; 83(6):431-438. PubMed ID: 39037547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update οn the diagnosis and management of systemic lupus erythematosus.
    Fanouriakis A; Tziolos N; Bertsias G; Boumpas DT
    Ann Rheum Dis; 2021 Jan; 80(1):14-25. PubMed ID: 33051219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort.
    Mok CC; Tse SM; Chan KL; Ho LY
    Lupus; 2018 Apr; 27(5):722-727. PubMed ID: 29087260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New and Established Therapeutic Options for the Treatment of Systemic Lupus Erythematosus].
    Goehner Schweizer K; Maurer B
    Praxis (Bern 1994); 2020; 109(5):341-345. PubMed ID: 32233759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.
    Mok CC
    Expert Rev Clin Immunol; 2017 Jan; 13(1):35-41. PubMed ID: 27417340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Lupus Erythematosus: A Review.
    Siegel CH; Sammaritano LR
    JAMA; 2024 May; 331(17):1480-1491. PubMed ID: 38587826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic lupus erythematosus: An approach to pharmacologic interventions.
    El Hussein MT; Wong C
    Nurse Pract; 2023 Jul; 48(7):37-46. PubMed ID: 37368557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
    J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.
    Thorbinson C; Oni L; Smith E; Midgley A; Beresford MW
    Paediatr Drugs; 2016 Jun; 18(3):181-95. PubMed ID: 26971103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the use of existing therapies in lupus.
    Croyle L; Morand EF
    Int J Rheum Dis; 2015 Feb; 18(2):129-37. PubMed ID: 25884457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for juvenile-onset systemic lupus erythematosus.
    Carreño L; López-Longo FJ; González CM; Monteagudo I
    Paediatr Drugs; 2002; 4(4):241-56. PubMed ID: 11960513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.